Drug intelligence / Profile preview

Influenza A virus subtype H1N1 hemagglutinin, recombinant

Development stage
Unknown
Lead developer
Novartis
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Influenza A virus subtype H1N1 hemagglutinin, recombinant is a laboratory-produced form of the viral surface glycoprotein hemagglutinin (HA) from the H1N1 strain of Influenza A. Hemagglutinin is essential for viral entry into host cells by binding to sialic acid-containing receptors on the cell surface and mediating membrane fusion during endocytosis. Recombinant forms are typically produced in mammalian or insect cell systems and are used as antigens in research, diagnostics, and vaccine development. The mechanism of action involves mimicking natural HA to elicit an immune response or serve as a target for neutralizing antibodies[2][4][5]. It plays a major role in determining host range restriction and virulence[2]. Recombinant HA proteins have been used in clinical trials for influenza immunization[3].

Other names
Influenza A H1N1 hemagglutinin recombinantRecombinant influenza A H1N1 hemagglutinin proteinHemagglutinin HA
02

Targets

SA (Sialic acid)HA (Hemagglutinin)Sialoglycan (Cell-surface sialoglycan)

Beyond the preview

Go deeper on Influenza A virus subtype H1N1 hemagglutinin, recombinant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza A virus subtype H1N1 hemagglutinin, recombinant.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call